LEO Pharma acquires global dersimelagon rights for up to $435 million

• Dersimelagon is an oral treatment for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), affecting approximately 5,000 U.S. patients, and would be the first oral treatment if approved
• FDA approval could come as early as 2027 with no anticipated delay between approval and commercial launch
• The deal includes additional downstream milestone payments and tiered royalties on net sales, part of LEO Pharma's strategy to expand into rare genetic skin disease treatments

LEO Pharma Acquires Dersimelagon Rights in $435 Million Deal

Danish pharmaceutical company LEO Pharma announced Tuesday it has acquired worldwide rights to dersimelagon from Tanabe Pharma for up to $435 million in upfront and near-term milestone payments, plus additional downstream milestones and tiered royalties on net sales.

Transaction Details:

The acquisition aligns with LEO Pharma's strategy to expand into rare genetic skin disease treatments as the company explores a potential stock market listing. This follows recent deals including a partnership with Boehringer Ingelheim on drug Spevigo (July 2025) and the acquisition of U.S. developer Replay (April).

Drug Profile:

Dersimelagon is an experimental oral treatment for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)—rare genetic disorders causing extreme sunlight sensitivity. The drug increases melanin production to protect against painful light-induced reactions. If approved, it would be the first oral treatment for these conditions.

Market Opportunity:

CEO Christophe Bourdon highlighted significant unmet medical need, estimating approximately 5,000 EPP patients in the U.S. alone. The FDA could approve dersimelagon for EPP and XLP as early as 2027, with Bourdon indicating no anticipated delay between approval and commercial launch.

Market Implications:

This acquisition strengthens LEO Pharma's rare disease portfolio and positions the company in an underserved niche market with limited competition. The deal demonstrates continued consolidation in specialty pharmaceuticals, particularly in orphan drug development where small patient populations can still generate substantial revenues given high unmet need and premium pricing potential.